<DOC>
	<DOCNO>NCT01889836</DOCNO>
	<brief_summary>Clinical trial phase I , randomize , double blind , 30 individual receive experimental vaccine 30 volunteer receive meningococcal C conjugate vaccine already license Brazil available National Immunization Program child less 12 month age . The primary outcome study evaluate safety profile vaccine test , allow application human . Secondly , investigator study immunogenicity evaluation correlate seroprotection meningococcal , defined World Health Organization ( WHO ) .</brief_summary>
	<brief_title>Safety Immunogenicity Study Young Adults Meningococcal Serogroup C Vaccine Produced Bio-Manguinhos</brief_title>
	<detailed_description>Study design - This clinical study Phase I , randomize , double blind 60 individual . 30 individual receive experimental vaccine Bio-Manguinhos/Fiocruz 30 individual receive meningococcal C conjugate vaccine use National Immunization Program . Location Study - Clinical Trials Unit Immunobiology Bio-Manguinhos/Fiocruz . Primary objective - Evaluate safety meningococcal C vaccine Bio-Manguinhos/Fiocruz use human . Secondary objective - To evaluate immunogenicity meningococcal C vaccine Bio-Manguinhos young adult . specific objectives 1 . To evaluate frequency / intensity adverse event occur 30 day vaccination . 2 . To evaluate seroconversion define pre-immunization serum nonreactive ( negative ) post-immunization reactor ( positive ) antigen , get title 8 ( rabbit complement ) target strain used test bactericidal power serum immunized volunteer , 4-fold increase titer follow vaccination compare pre-vaccination antibody titer immunization .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Both sex . Age 18 50 . Available followup period study Willing provide name , address , telephone number information contact study learn necessary ( eg case lack schedule visit ) . Willing strictly follow study protocol . Ability understand sign consent form . Understanding impossibility participate another clinical trial time participate study . Intellectual level allow fill form registration symptoms home . Acceptance serological test human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) Hepatitis C virus ( HCV ) . Be good health , significant medical history . Physical examination screen without significant clinical change . Screening laboratory test within normal limit establish laboratory abnormal value small 1 degree . Additional criterion female : Negative pregnancy test application vaccine dose , woman childbearing age . Pregnant breastfeeding . Personal history : Meningitis kind . Serious adverse reaction vaccination , difficulty breathing , angioedema anaphylaxis . Severe adverse reaction relate prior immunization tetanus / diphtheria vaccine alone combination vaccine . Vaccination tetanus diphtheria vaccine alone combination vaccine last two year . Use allergy shot antigen within 14 day less prior vaccination . Immunoglobulin last 12 month vaccination . Use blood product last 12 month vaccination . Use vaccine 30 day vaccination . Chronic use medication except homeopathic trivial Nasal saline vitamin . Previous use cytotoxic immunosuppressive medication . Are acceptable individual make use type immunosuppressive medication dos six month , nasal steroid allergic rhinitis dermatitis topical corticosteroid uncomplicated . Use investigational medication period 1 year prior vaccination . Unstable asthma require urgent care , hospitalization intubation last two year , require use oral intravenous corticosteroid . Severe anaphylaxis angioedema . Neurological , cardiovascular , respiratory , hepatic , renal , hematologic , rheumatologic autoimmune clinically significant ( disease lead hospitalization prolong treatment ) . Coagulopathy diagnose medical report capillary fragility ( eg bruise bleed without justifiable cause ) . Seizures , except fever , 2 year age . Psychiatric illness impairs adherence protocol , psychosis , neurosis obsessivecompulsive disorder , bipolar disorder treat , diseases require lithium treatment suicidal ideation last five year prior enrollment . Active malignancy ( eg type cancer ) treat recourse study . Sickle cell anemia . Asplenia ( absence spleen removal ) . HIV positive screen test history immunosuppressive disease . Positive serology hepatitis C screen test . HBsAg positive screening test . Alcoholism ( CAGE criterion ) , use detection abusive drinker alcoholic , validate population sensitivity 88 % specificity 83 % two response among four possible , affirmative . Use / abuse drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>meningococcal conjugate vaccine serogroup C</keyword>
	<keyword>Prevention</keyword>
</DOC>